450 completed, 68 unknown, 38 terminated, 34 recruiting. 193 Phase 1, 156 Phase 2, 136 Phase 3, 51 Not applicable, 42 Phase 4.
Follow Mononegavirales Infections: new trials by email Literature Review of Mononegavirales Infections trials Research Report on Mononegavirales Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers Ervebo, Inmazeb - Ebola Virus Disease | Phase 2 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 132 | 2027-01-01 | 2026-01-22 |
| Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - DRC DECIPHER bioassay - Ebola Hemorrhagic Fever | Not yet recruiting | Institute of Tropical Medicine, Belgium | 100 | 2027-01-01 | 2026-07-07 | |
| Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - GUINEA FORTIFIEDx and DECIPHER bioassays - Ebola Hemorrhagic Fever, Lassa Hemorrhagic Fever | Not yet recruiting | Institute of Tropical Medicine, Belgium | 150 | 2027-01-01 | 2026-07-02 | |
| A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults Bivalent RSV Vaccine (IN006), Placebo - Respiratory Syncytial Virus Infections | Phase 1 | Not yet recruiting | Shenzhen Shenxin Biotechnology Co., Ltd | 200 | 2026-12-01 | 2026-04-13 |
| Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Virus Infection. SYH2066, Placebo - Respiratory Syncytial Virus Infections | Phase 2 | Not yet recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 80 | 2026-11-13 | 2026-10-20 |
| Assessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region Vaccination Coverage Among Pregnant Women | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 1605 | 2026-11-01 | 2026-10-20 | |
| Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo Candidate BDBV vaccine, Active comparator - Ebola Hemorrhagic Fever, Bundibugyo Virus Disease | Phase 2 / Phase 3 | Not yet recruiting | Jean-Pierre Van geertruyden | 3620 | 2026-10-20 | 2026-10-05 |
| Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset ABRYSVO - Respiratory Syncytial Virus Infections | Not yet recruiting | Pfizer | 1 | 2026-10-15 | 2026-09-24 | |
| The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation Clesrovimab - RSV Infection | Phase 4 | Not yet recruiting | Emory University | 24 | 2026-09-01 | 2026-09-17 |
| EBOla Post-Exposure Prophylaxis Ervebo, Inmazeb - Ebola Virus Disease | Phase 3 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 160 | 2026-09-01 | 2026-01-22 |
| Internal Jugular Vein Respiratory Variability as a Marker of Disease Severity in Infant Bronchiolitis Point-of-Care Ultrasonography - Acute Bronchiolitis, Viral Bronchiolitis | Not yet recruiting | Eskisehir Osmangazi University | 120 | 2026-09-01 | 2026-08-21 | |
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine - Measles, Mumps | Phase 3 | Not yet recruiting | GlaxoSmithKline | 1860 | 2026-08-11 | 2026-08-03 |
| A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus zelicapavir, Placebo - RSV Infection, RSV | Phase 2 | Recruiting | Enanta Pharmaceuticals, Inc | 150 | 2026-07-09 | 2026-07-20 |
| Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections SARS CoV 2 Infection, RSV Infections | Not yet recruiting | Fabiana Sherine Ganem dos Santos | 150 | 2026-07-01 | 2026-06-11 | |
| Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure ERVEBO® (rVSV∆G-ZEBOV-GP) - Ebola Vaccine | Phase 3 | Withdrawn | Universitätsklinikum Hamburg-Eppendorf | 2026-06-01 | 2026-06-04 | |
| Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming. Booster vaccination - Rabies (Healthy Volunteers) | Phase 3 | Not yet recruiting | Institute of Tropical Medicine, Belgium | 561 | 2026-05-15 | 2026-03-06 |
| Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older. Recombinant Respiratory Syncytial Virus Vaccine(CHO cell)(Adjuvanted), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Blank adjuvant) - Respiratory Syncytial Virus Infections | Phase 1 / Phase 2 | Recruiting | Ab&B Bio-tech Co., Ltd.JS | 470 | 2026-05-14 | 2026-05-27 |
| Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France saliva sampling, Nasopharyngeal swab - Respiratory Tract Infections (RTI), Influenza -Like Illness | Recruiting | Institut National de la Santé Et de la Recherche Médicale, France | 25000 | 2026-05-14 | 2026-08-03 | |
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age MMRVNS, MMRV - Measles, Measles-Mumps-Rubella+Chickenpox Vaccine | Phase 3 | Recruiting | GlaxoSmithKline | 1209 | 2026-05-11 | 2026-07-08 |
| A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health rVSVΔG-SUDV-GP, Placebo - Sudan Virus Disease | Phase 1 | Recruiting | International AIDS Vaccine Initiative | 112 | 2026-05-08 | 2026-09-21 |
Showing 20 of 667. Sign in to see all of them.
Respiratory Syncytial Virus Infections (302) · Measles (124) · Hemorrhagic Fever, Ebola (102) · Rabies (95) · Mumps (81) · Rubella (81) · Chickenpox (45) · Virus Diseases (28) · Paramyxoviridae Infections (25) · Influenza, Human (23) · COVID-19 (21) · Respiratory Tract Infections (21) · Hemorrhagic Fevers, Viral (18) · Bronchiolitis (15) · Infections (13)
RNA Virus Infections (661) · Infections (654) · Virus Diseases (639) · Paramyxoviridae Infections (437) · Pneumovirus Infections (302) · Morbillivirus Infections (125) · Filoviridae Infections (105) · Hemorrhagic Fevers, Viral (98) · Rhabdoviridae Infections (94) · Respiratory Tract Diseases (87) · Togaviridae Infections (83) · Mouth Diseases (81) · Parotid Diseases (81) · Parotitis (81)
Rabies Vaccines (29) · measles, mumps, rubella, varicella vaccine (23) · Measles-Mumps-Rubella Vaccine (20) · Saline Solution (14) · Chickenpox Vaccine (12) · Measles Vaccine (10) · Vaccines (10) · EDP-938 (8) · Hepatitis A Vaccines (8) · Rubella Vaccine (8) · Palivizumab (7) · nirsevimab (7) · sisunatovir (7) · ziresovir (7) · 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (6)
GlaxoSmithKline (66) · National Institute of Allergy and Infectious Diseases (NIAID) (56) · Sanofi Pasteur, a Sanofi Company (26) · Merck Sharp & Dohme LLC (21) · Enanta Pharmaceuticals, Inc (14) · University of Oxford (14) · Pfizer (13) · MedImmune LLC (10) · Queen Saovabha Memorial Institute (10) · Gilead Sciences (8) · Bandim Health Project (7) · Institute of Tropical Medicine, Belgium (7) · Janssen Vaccines & Prevention B.V. (7) · Novartis Vaccines (7) · Shanghai Ark Biopharmaceutical Co., Ltd. (7)
United States (239) · China (75) · United Kingdom (64) · Australia (47) · Germany (42) · Spain (40) · France (39) · Belgium (33) · Canada (33) · Japan (29) · South Africa (29) · Thailand (29) · Finland (26) · Italy (26) · Poland (23)
Ruth A. Karron, MD (13) · Suda Sibunruang, MD (6) · Richard T Davey, M.D. (4) · Alexander D Douglas (3) · Alison Heald, MD (3)
PMID 28647166, PMID 31951765, PMID 34774184, PMID 38921800, PMID 25426834, PMID 25483635, PMID 25830326, PMID 26546548, PMID 26659569, PMID 28017642, PMID 29401325, PMID 29509911, PMID 29509929, PMID 30407513, PMID 30855742, PMID 31211158, PMID 32813276, PMID 34930928, PMID 35182042, PMID 37468530, PMID 37821317, PMID 38603720, PMID 38902186, PMID 10342702, PMID 11009541, PMID 11228365, PMID 11395204, PMID 11672911, PMID 12443658, PMID 12798618, PMID 14506371, PMID 14722149, PMID 14741143, PMID 15082642, PMID 15188713, PMID 15356783, PMID 1538192, PMID 15577929, PMID 15626943, PMID 15659474, PMID 15983268, PMID 16094218, PMID 16375711, PMID 16390959, PMID 16452343, PMID 16567978, PMID 16804432, PMID 17060336, PMID 17156899, PMID 17332177
2019 (9), 2023 (9), 2014 (7), 2018 (7), 2016 (5), 2015 (4), 2025 (4), 2017 (3), 272201300017C-18-0-1 (1), 5UM1AI148684-04 (1), R01AI070018 (1), R01AI179874 (1), R01HD105678 (1)